These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21830963)

  • 21. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Achievement of therapeutic objectives].
    Mantilla T
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():20-4. PubMed ID: 25043543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
    Chan DC; Watts GF
    Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipids, statins and cardiovascular disease.
    Cheifitz R
    Climacteric; 2008 Aug; 11(4):347-8; author reply 348-50. PubMed ID: 18645702
    [No Abstract]   [Full Text] [Related]  

  • 26. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy of dyslipidemias in the adult population.
    Vigna GB; Fellin R
    Expert Opin Pharmacother; 2010 Dec; 11(18):3041-52. PubMed ID: 20958118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrate use in the United States and Canada.
    Tenenbaum A; Fisman EZ
    JAMA; 2011 Jul; 306(2):157; author reply 158-9. PubMed ID: 21750290
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of fibrates in the United States and Canada.
    Jackevicius CA; Tu JV; Ross JS; Ko DT; Carreon D; Krumholz HM
    JAMA; 2011 Mar; 305(12):1217-24. PubMed ID: 21427374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
    Dodson PM
    Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Questioning the benefits of statins.
    Mazowita G
    CMAJ; 2005 Nov; 173(10):1210; author reply 1210. PubMed ID: 16275979
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients.
    Howes LG
    Diabetes Obes Metab; 2006 Jan; 8(1):8-14. PubMed ID: 16367877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin-fibrate combination therapy.
    Feeman WE
    Am J Cardiol; 2008 May; 101(10):1521. PubMed ID: 18471475
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prevention: dyslipidaemia.
    Pignone M
    Clin Evid; 2005 Dec; (14):142-50. PubMed ID: 16620402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.